-
Markets
athexgroup.grAthens Exchange GroupRead moreTogether for a unified, stronger European capital market.
-
Equities
Sustainable finance2025 Euronext ESG Trends ReportRead moreA data-driven snapshot of how Euronext-listed companies are advancing their Environmental, Social and Governance (ESG) practices.
-
Indices
Access the white paperInvesting in the future of Europe with innovative indicesRead moreThe first edition of the Euronext Index Outlook series with a particular focus on the European Strategic Autonomy Index.
-
ETFs
The European market place for ETFsEuronext ETF EuropeRead moreInvestors benefit from a centralised market place that will not only bring transparency but also better pricing due to the grouping of liquidity.
- Funds
-
Fixed Income
European Defence BondsGroupe BPCE lists the first bondRead moreFirst financial institution in Europe to issue a bond dedicated to the defence sector
- Structured Products
-
Derivatives
Where European Government Bonds Meet the FutureTrade Mini Bond FuturesRead moreTrade mini bond futures on main European government bonds
-
Commodities
- Overview
- Agricultural quotes
- Power Derivatives
- Milling Wheat derivatives
- Corn derivatives
- Spread contracts
- Rapeseed derivatives
- Durum Wheat derivatives
- Dairy derivatives
- Salmon derivatives
- Container Freight Futures
- Delivery & settlement
- Specifications & arrangements
- Commitments of Traders (CoT) report
- Commodity brokers
Take control of unpredictable dairy pricesEuropean Dairy DerivativesRead moreFutures and options on butter and skimmed milk powder now trading.
-
Resources
Designed to help students navigate the complexities of financial marketsEuronext Trading gameRead moreJoin the Euronext Trading Game and step into capital markets. Learn from today’s leaders, explore sustainable opportunities, and trade with confidence.
Novartis sets lower annual sales growth target through 2031
By Bhanvi Satija and Marleen Kaesebier
LONDON, Nov 19 (Reuters) - Swiss drugmaker Novartis set a target of annual sales growth of 5% through 2031 on Thursday, relying on a handful of drugs already on the market to offset looming patent expiries and recover from a string of late-stage trial setbacks.
The new target, at constant currencies, is lower than a 5% to 6% annual sales growth range it set last year for 2025-2030.
Shares in the company fell 2% in early trading.
Novartis is seeking to boost investor confidence in its growth plans beyond 2030 after several late-stage clinical study setbacks this year led to a $2.2 billion writedown in the third quarter.
By 2031, breast cancer drug Kisqali and Cosentyx for autoimmune diseases, two of Novartis' best-selling medicines, will face competition from cheaper rivals. Its heart drug Entresto is already seeing tough generic competition and is set to lose $4 billion in sales this year.
The setbacks included the failure of del-desiran, a muscle weakness therapy that Novartis acquired as part of its $12 billion Avidity deal. That has drawn close investor scrutiny to CEO Vas Narasimhan's dealmaking strategy.
Narasimhan said that the company's mid-term targets do not assume any large acquisitions.
"We would expect the contribution of M&A and BD (business development) to be consistent with what we've done in the past," he said.
Narasimhan said he expected most of the company's growth beyond 2031 to come from medicines developed internally.
In the last decade, Novartis has spent over $100 billion on developing medicines internally and $63 billion on business development activities including acquisitions.
Cosentyx and Kisqali are expected to bring in combined sales of $14 billion in 2031, down from $16.6 billion in 2030, according to Visible Alpha estimates.
The company expects sales from its anti-inflammatory drug Rhapsido and multiple sclerosis drug Kesimpta, among others, to offset some of that drop in sales.
It forecast peak sales of Kisqali at $10 billion, and lifted its peak sales forecast for Kesimpta to $8 billion from $6 billion, and for leukemia drug Scemblix and cholesterol-lowering treatment Leqvio to $5 billion each from $4 billion.
(Reporting by Bhanvi Satija and Marleen Kaesebier;Editing by Dave Graham and Emelia Sithole-Matarise)
Find it fast
Looking for more insights? Explore our other news sections for updates on sustainable finance, companies and financial education